𝗦𝗲𝗺𝗮𝗴𝗹𝘂𝘁𝗶𝗱𝗲 𝗧𝗵𝗲𝗿𝗮𝗽𝘆 𝗠𝗮𝗿𝗸𝗲𝘁 𝗛𝗼𝗹𝗱𝘀 𝗥𝘀 𝟭𝟬𝟬 𝗖𝗿𝗼𝗿𝗲 𝗜𝗻 𝗘𝘅𝗰𝗲𝘀𝘀 𝗦𝘁𝗼𝗰𝗸
The semaglutide therapy market faces high inventory levels. Industry sources report excess stock worth approximately Rs 100 crore in the trade channel.
Key market details:
- Stockists and wholesalers hold 50 to 60 days of inventory.
- Normal inventory levels range from 30 to 45 days.
- Channel partners stopped fresh purchases from pharmaceutical companies.
- Value growth slowed to 6% in May.
- Unit growth reached 12% in May.
- April saw 50% value growth and 88% volume growth.
The surge in April followed the March 20 patent expiry of semaglutide. Companies including Torrent, Sun Pharma, and Dr Reddy's launched generic brands.
Other market facts:
- Mounjaro sales reached Rs 136 crore in May.
- Mounjaro sales grew by 12%.
- The organized pharma retail market grew nearly 11% in May.
- Semaglutide and tirzepatide belong to the GLP-1 receptor agonist class.
- These drugs manage type 2 diabetes and obesity.
Government advisories from April require specialists to prescribe GLP-1 therapies. Industry executives link the sales slowdown to these prescribing restrictions.